Prospective Grant of Exclusive License: Treatment of Cardiovascular Conditions With Nitrite Therapy, 46496 [06-6880]
Download as PDF
<![CDATA[
46496
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
Dated: July 28, 2006.
Steven Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 06–6871 Filed 8–11–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Treatment of Cardiovascular
Conditions With Nitrite Therapy
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
jlentini on PROD1PC65 with NOTICES
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. § 209(c)(1) and 37 CFR
§ (a)(1)(I), that the National Institutes of
Health (NIH), Department of Health and
Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the invention
embodied in: PCT patent application
PCT/US2004/041256 filed December 9,
2004, entitled: ‘‘Methods for
Suppressing an Immune Response or
Treating a Proliferative Disorder’’ [HHS
Reference Number: E–259–2003/0–PCT–
02], to Sahajanand Medical
Technologies Pvt. Ltd., registered as a
private limited company in accordance
with the Companies Act of India, having
a principle place of business in Surat,
India and U.S. headquarters in
Gaithersburg, Maryland. The field of use
may be limited to the use of 2-(4piperazinyl)-8-phenyl-4H-1-benzopyran4-one (LY303511), for the treatment and
prevention of stenosis and restenois
and/or other proliferative disorders. The
United States of America is an assignee
of the patent rights in these inventions.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
October 13, 2006 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Susan Carson, D. Phil, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
E-mail: carsonsu@od.nih.gov;
Telephone: (301) 435–5020; Facsimile:
(301) 402–0220.
SUPPLEMENTARY INFORMATION: The
search for specific kinase inhibitors is
an active area of drug development as
there is a continued need for effective
VerDate Aug<31>2005
17:58 Aug 11, 2006
Jkt 208001
anti-proliferative therapeutics with
acceptable toxicities. The core invention
is a novel method of use of one of the
4H-1-benzopyran-4-one derivatives
(LY303511) which has been shown to
target mTOR and casein kinase 2 (CK2)
without affecting P13K activity (JPET,
May 26, 2005, doi: 10.1124/
jpet.105.083550). Proof of concept data
is available in an in vivo human
zenograft PC-3 prostate tumor model,
without observed toxicity. In vitro data
suggests that (2-(4-piperazinyl)-8pheynl-4H-1 benzopyran-4-one and
derivatives may be effective in treating
inflammatory, autoimmune and other
proliferative disorders including
restenosis and a variety of cancers.
Method of use claims are directed to
derivatives of 2-(4-piperazinyl)substituted 4H-1-benzopyran-4-one
compounds as anti-proliferative,
immunosuppressive, anti-inflammatory,
anti-restenosis and anti-neoplastic
agents.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 24, 2006
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 06–6880 Filed 8–11–06; 8:45am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Privacy Act of 1974; Proposed Altered
System of Records
National Institutes of Health
(NIH), Department of Health and Human
Services (DHHS).
ACTION: Notification of Proposed Altered
System of Records.
AGENCY:
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
SUMMARY: In accordance with the
requirements of the Privacy Act of 1974,
as amended (Privacy Act), the National
Institutes of Health (NIH) hereby
publishes a notice of a proposal to alter
System of Records, No. 09–25–0168,
‘‘Invention, Patent, and Licensing
Documents Submitted to the Public
Health Service by its Employees,
Grantees, Fellowship Recipients, and
Contractors, HHS/NIH/OD.’’ NIH
proposes a new legal authority for the
maintenance of the System to read: 15
U.S.C. 3710, 3710a, 3710c & 3710d and
35 U.S.C. 200 et seq. provide authority
to maintain the records; 37 CFR part 401
‘‘Rights to Inventions Made by
Nonprofit Organizations and Small
Business Firms under Government
Grants, Contracts, and Cooperative
Agreements;’’ 37 CFR part 404
‘‘Licensing of Government Owned
Inventions;’’ and 45 CFR part 7
‘‘Employee Inventions.’’ NIH is also
proposing new routine uses for this
System.
These records will be maintained by
the Office of Technology Transfer
(OTT), OIR/OD; Office of Financial
Management (OFM), OD; Office of
Reports and Analysis (ORA), OER/OD;
Health and Human Services Technology
Development Coordinators and HHS
Contract Attorneys who retain files
supplemental to the records maintained
by the Office of Technology Transfer;
and the Extramural Inventions and
Technology Resources Branch, OPERA/
OER/OD.
DATES: The NIH invites interested
parties to submit comments on or before
September 13, 2006. The NIH will send
a Report of the Proposed Altered System
to the Congress and to the Office of
Management and Budget (OMB). The
proposed altered System of Records will
be effective 40 days from the date
submitted to the OMB, unless NIH
receives comments that would result in
a contrary determination.
ADDRESSES: You may submit comments,
identified by the Privacy Act System of
Records Number 09–25–0168, by any of
the following methods:
• Federal eRulemaking Portal: https://
regulations.gov. Follow the instructions
for submitting comments.
• E-mail:
nihprivacyactofficer@mail.nih.gov and
include PA SOR number 09–25–0168 in
the subject line of the message.
• Phone: (301) 496–2832 (not a tollfree number).
• Fax: (301) 402–0169.
• Mail: NIH Privacy Act Officer,
Office of Management Assessment,
National Institutes of Health, 6011
Executive Boulevard, Suite 601, MSC
7669, Rockville, Maryland 20892.
E:\FR\FM\14AUN1.SGM
14AUN1
]]>Agencies
[Federal Register Volume 71, Number 156 (Monday, August 14, 2006)]
[Notices]
[Page 46496]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-6880]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Treatment of
Cardiovascular Conditions With Nitrite Therapy
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. Sec. 209(c)(1)
and 37 CFR Sec. (a)(1)(I), that the National Institutes of Health
(NIH), Department of Health and Human Services (HHS), is contemplating
the grant of an exclusive license to practice the invention embodied
in: PCT patent application PCT/US2004/041256 filed December 9, 2004,
entitled: ``Methods for Suppressing an Immune Response or Treating a
Proliferative Disorder'' [HHS Reference Number: E-259-2003/0-PCT-02],
to Sahajanand Medical Technologies Pvt. Ltd., registered as a private
limited company in accordance with the Companies Act of India, having a
principle place of business in Surat, India and U.S. headquarters in
Gaithersburg, Maryland. The field of use may be limited to the use of
2-(4-piperazinyl)-8-phenyl-4H-1-benzopyran-4-one (LY303511), for the
treatment and prevention of stenosis and restenois and/or other
proliferative disorders. The United States of America is an assignee of
the patent rights in these inventions.
DATES: Only written comments and/or application for a license, which
are received by the NIH Office of Technology Transfer on or before
October 13, 2006 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Susan Carson, D. Phil, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; E-mail: carsonsu@od.nih.gov;
Telephone: (301) 435-5020; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: The search for specific kinase inhibitors is
an active area of drug development as there is a continued need for
effective anti-proliferative therapeutics with acceptable toxicities.
The core invention is a novel method of use of one of the 4H-1-
benzopyran-4-one derivatives (LY303511) which has been shown to target
mTOR and casein kinase 2 (CK2) without affecting P13K activity (JPET,
May 26, 2005, doi: 10.1124/jpet.105.083550). Proof of concept data is
available in an in vivo human zenograft PC-3 prostate tumor model,
without observed toxicity. In vitro data suggests that (2-(4-
piperazinyl)-8-pheynl-4H-1 benzopyran-4-one and derivatives may be
effective in treating inflammatory, autoimmune and other proliferative
disorders including restenosis and a variety of cancers. Method of use
claims are directed to derivatives of 2-(4-piperazinyl)-substituted 4H-
1-benzopyran-4-one compounds as anti-proliferative, immunosuppressive,
anti-inflammatory, anti-restenosis and anti-neoplastic agents.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 24, 2006
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 06-6880 Filed 8-11-06; 8:45am]
BILLING CODE 4140-01-M
